Merck Receives Positive EU Opinion to Expand ENFLONSIA Authorization
The EMA’s CHMP recommended expanding ENFLONSIA’s indication to children up to 24 months who remain vulnerable to severe RSV disease through their second RSV season.
The EMA’s CHMP recommended expanding ENFLONSIA’s indication to children up to 24 months who remain vulnerable to severe RSV disease through their second RSV season.